## ABSTRACT

## SUBSTITUTED TETRAHYDROISOQUINOLINES

The invention is directed to physiologically active compounds of formula (I):-



(I)

wherein:-

$R^1$ represents optionally substituted aryl, optionally substituted heteroaryl, $R^3NH\text{-}Ar^1\text{-}L^2$- or $R^3$-NH-C(=O)-NH-$Ar^2$-$L^2$-; $R^3$ represents aryl or heteroaryl; $Ar^1$ represents a saturated, partially saturated or fully unsaturated 8- to 10-membered bicyclic ring system containing at least one heteroatom selected from O, S or N; $Ar^2$ represents aryldiyl or heteroaryldiyl; $L^1$ represents a linkage, such as an alkylene linkage; $L^2$ represents an alkylene chain linkage; $R^2$ represents hydrogen, halogen, $C_{1-4}$alkyl or $C_{1-4}$alkoxy; and Y is carboxy or an acid bioisostere;

but excluding compounds where an oxygen, nitrogen or sulfur atom is attached directly to a carbon carbon multiple bond of an alkenylene or alkynylene residue;

and the corresponding N-oxides and ester prodrugs thereof, and the pharmaceutically acceptable salts and solvates of such compounds, and the N-oxides and ester prodrugs thereof.

Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 ($\alpha4\beta1$).